Review



bb21217  (Bristol Myers)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Bristol Myers bb21217
    Clinical Response of BCMA CAR T Cell Therapies in Multiple Myeloma.
    Bb21217, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bb21217/bcma+targeted+cart+cell+therapy+bb21217/pmc09263699-12-0-4
    Average 90 stars, based on 1 article reviews
    bb21217 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm"

    Article Title: Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2022.925818

    Clinical Response of BCMA CAR T Cell Therapies in Multiple Myeloma.
    Figure Legend Snippet: Clinical Response of BCMA CAR T Cell Therapies in Multiple Myeloma.

    Techniques Used:

    Related Articles

    other:

    Article Title: Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
    Article Snippet: bb21217 ( ) , Bristol Myers Squibb/bluebird bio , CRS 1%, neurotoxicity 4% , 75% , ORR: 69%; ≥VGPR: 58%; sCR/CR: 28% , estimated median DOR: 27.2 m.



    Similar Products

    o capability • bcma car t bb2121 bb21217  (Celgene)
    86
    Celgene o capability • bcma car t bb2121 bb21217
    O Capability • Bcma Car T Bb2121 Bb21217, supplied by Celgene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bb21217/bb2121/sec_filing____816284_slash_000114420418002936_slash_tv483708_ex99___1-29-13-30
    Average 86 stars, based on 1 article reviews
    o capability • bcma car t bb2121 bb21217 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    bb21217  (Bluebird Bio)
    90
    Bluebird Bio bb21217
    Products targeting BCMA CAR-T for the treatment of multiple myeloma and major clinical adverse reactions.
    Bb21217, supplied by Bluebird Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bb21217/bb21217/pmc11598525-46-0-2
    Average 90 stars, based on 1 article reviews
    bb21217 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    bb21217  (Celgene)
    90
    Celgene bb21217
    Products targeting BCMA CAR-T for the treatment of multiple myeloma and major clinical adverse reactions.
    Bb21217, supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bb21217/bb21217/us12006370-409-141-142
    Average 90 stars, based on 1 article reviews
    bb21217 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    bb21217 product  (Bluebird Bio)
    90
    Bluebird Bio bb21217 product
    Products targeting BCMA CAR-T for the treatment of multiple myeloma and major clinical adverse reactions.
    Bb21217 Product, supplied by Bluebird Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bb21217/bb21217/pm35199207-62-10-6
    Average 90 stars, based on 1 article reviews
    bb21217 product - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    bb21217  (Bristol Myers)
    90
    Bristol Myers bb21217
    Clinical Response of BCMA CAR T Cell Therapies in Multiple Myeloma.
    Bb21217, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bb21217/bcma+targeted+cart+cell+therapy+bb21217/pmc09263699-12-0-4
    Average 90 stars, based on 1 article reviews
    bb21217 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Products targeting BCMA CAR-T for the treatment of multiple myeloma and major clinical adverse reactions.

    Journal: Frontiers in Immunology

    Article Title: Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma

    doi: 10.3389/fimmu.2024.1435934

    Figure Lengend Snippet: Products targeting BCMA CAR-T for the treatment of multiple myeloma and major clinical adverse reactions.

    Article Snippet: Bb21217 , Bluebird Bio , R&D terminated , NCT03274219 (Phase I) , CRS (75%) Neurologic toxic effect (15%) , ( ) .

    Techniques:

    Clinical Response of BCMA CAR T Cell Therapies in Multiple Myeloma.

    Journal: Frontiers in Oncology

    Article Title: Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm

    doi: 10.3389/fonc.2022.925818

    Figure Lengend Snippet: Clinical Response of BCMA CAR T Cell Therapies in Multiple Myeloma.

    Article Snippet: bb21217 ( ) , Bristol Myers Squibb/bluebird bio , CRS 1%, neurotoxicity 4% , 75% , ORR: 69%; ≥VGPR: 58%; sCR/CR: 28% , estimated median DOR: 27.2 m.

    Techniques: